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Abstract
Background Resection of isolated hepatic or pulmonary
metastases from colorectal cancer is widely accepted and
associated with a 5-year survival rate of 25–40%. The value
of aggressive surgical management in patients with both
hepatic and pulmonary metastases still remains a contro-
versial area.
Materials and methods A retrospective review of 1,497
patients with colorectal carcinoma (CRC) was analysed. Of
73 patients identified with resection of CRC and, at some
point in time, both liver and lung metastases, 17 patients
underwent metastasectomy (resection group). The remain-
ing 56 patients comprised the non-resection group. Primary
tumour, hepatic and pulmonary metastases of all patients
were surgically treated in our department of surgery, and
the results are that of a single institution.
Results The resection group had a 3-year survival of 77%, a
5-year survival of 55% and a 10-year survival of 18%;
median survival was 98 months. The longest overall
survival was 136 months; six patients are still alive. In the
resection group, overall survival was significantly higher
than in the non-resection group (p<0.01). Independent from
the chronology of metastasectomy, 5-year survival was
55% with respect to the primary resection, 28% with
respect to the first metastasectomy and 14% with respect to
the second metastasectomy. A disease-free interval
(>18 months), stage III (UICC) and age (<70 years) were
found to be significant prognostic factors for overall
survival.
Conclusion Our report strongly supports aggressive surgi-
cal therapy in patients with both hepatic and pulmonary
metastases from CRC. Overall survival for surgically
treated selected patients with both hepatic and pulmonary
metastases from CRC is comparable to hepatic or pulmo-
nary metastasectomy. Simultaneous metastases tend to have
a poorer outcome than metachronous metastases.
Keywords Colorectalcancer.Lungmetastases.
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Introduction
Second to lung cancer in men and breast cancer in women,
colorectal carcinoma (CRC) has increased in incidence over
the past 20 years. About half of the patients undergoing
radical resection of CRC will develop metastatic disease [1,
2], mostly to the liver (33%) and the lungs (22%) [3]. The
overall 5-year survival rate of potentially radical resected
CRC has been estimated to 71% [4]. Patients with untreated
metastatic CRC have a poor outcome with a 5-year
probability of survival of <5% [5]. Conventional manage-
ment of metastatic CRC has been directed at palliation. But
chemotherapy-based treatment regime seldom produced
long-term survival in these patients. These disappointing
results have led to the general acceptance of surgical
treatment of patients with metastatic disease to the liver or
to the lung. Nowadays, resection of hepatic metastases has
become an effective treatment with a reported 5-year
survival of 39% [6]. Likewise, the resection of lung
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21% to 43% [7–9]. The discouraging results of chemother-
apy along with the encouraging survival rates in resected
patients have led to the attempts to expand the indication
for surgical treatment of metastatic CRC in patients with
metastases both to the liver and to the lung. Several reports
from other institutions showed a survival rate of these
highly selected patients similar to patients who underwent
surgical resection of metastases confined only to the lung
[10–12]. However, the results are limited by a small
number of patients.
We reviewed the characteristics of our patients with
radical (R0) resection in an attempt to evaluate the efficacy
of resection of both hepatic and pulmonary metastases.
Materials and methods
A retrospective single-centre data analysis of all patients with
R0 resected hepatic and pulmonary metastases of colorectal
cancer was performed. The study period ranged from January
1990 toFebruary 2008. All patientswith radical (R0) resected
CRC and synchronous or metachronous hepatic and pulmo-
nary metastases were included. Selection criteria for resection
of the metastatic lesion were a controlled primary tumour and
controlled or controllable lesions.
Preoperative staging included coloscopy with histopath-
ological biopsy, endoscopic ultrasound and CT scan of
abdomen and chest. Postoperative staging of CRC was
classified according to the UICC (Union internationale
contre le cancer) guidelines [13]. Surgical data and his-
topathological findings were evaluated retrospectively.
Follow-up data were obtained through a standardised
surveillance programme for colorectal cancer including
coloscopy, liver ultrasonography, chest radiography and
determination of carcinoembryonic antigen (CEA) level. In
the case of a suspected lesion or elevated CEA level, further
diagnostic imaging (CT scan, PET) was added. Surgery was
indicated in all cases of newly detected pulmonary or
hepatic lesions.
By definition, metastases occurring within 3 months
after resection of the primary tumour were termed synchro-
nous metastases. In contrast, metastases that occurred after
a disease-free interval of more than 3 months after primary
resection were termed metachronous.
Liver resections were classified as solitary or multiple
wedge resections, lobectomy, segmentectomy or hemi-
hepatectomy. Additional hyperthermic or radiofrequency
ablation in combination with liver resection was also
assessed. Pulmonary resections were classified as wedge
resection, segmentectomy or laser ablation. Bilateral lung
metastases or recurrent lesions were not a contraindication.
The medical records of all patients with pulmonary and
hepatic metastases of colorectal cancer were reviewed with
regards to age, sex, disease-free interval, mortality, mor-
bidity and survival. Postoperative mortality was defined as
any death that occurred within 30 days after either lung or
liver resection or during the same period of hospitalisation.
Statistics
Statistical analysis was performed with SPSS 17.0 (SPSS
Inc., Chicago, IL, USA). The significance of relations
between patient groups and pathological parameters were
analysed using Pearson’s chi-square or Fisher’s exact test.
Survival analysis was performed using Kaplan–Meier [14]
(for univariate analysis) and Cox regression model (multi-
variable model) with the date of the primary tumour
resection as the starting point. Survival curves were
compared using the log-rank test. A two-sided p < 0.05
was considered significant.
Results
Between January 1990 and February 2008, a total of 1,497
patients underwent radical (R0) surgical resection of
colorectal cancer at the Department of Surgery, University
of Schleswig-Holstein, Campus Luebeck. Among these,
177 patients developed metastases confined to the liver (39
synchronous, 138 metachronous), and 68 patients had
undergone resection of pulmonary metastases (three syn-
chronous, 65 metachronous).
Seventy-three patients developed both hepatic and pulmo-
nary metastases (17 synchronous, 56 metachronous). Forty-
fivepatientsweresurgicallytreated(R0)inthefirstplace.The
remaining 27 patients were not surgically treated due to the
following reasons: Seven patients had a diffuse metastatic
spread of both liver and lung, three had multiple lesions in the
liver (one with an additional carcinoma of the colon, ten local
recurrences combined with metastases to the liver or the lung
and seven patientswith simultaneous metastatic occurrence in
liver, lung and a third localisation (bone, brain, lymph nodes).
These patients were treated by chemotherapy (CTX), radio-
therapy(RTX),immunotherapy(ITX) ora combination.They
had no surgical treatment at all.
When the tumour occurred in a further, second location,
only 17 of these 45 patients could receive radical surgical
treatment, whilst in the remaining 28 patients, a non-
surgical treatment (radiotherapy, chemotherapy, immuno-
therapy or any combination) was performed due to reduced
general condition or multiloculary recurrence.
Of the highly selected group of patients with both
hepato-pulmonary metastases, only a small number of 17
patients with both R0 resected metastases of CRC were
identified in our retrospective study (Fig. 1).
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(seven patients with combined chemo-radiotherapy, two
patients only radiotherapy). Average overall survival (OS)
in this group was 56.2 months (SD ± 11.4), median
46.8 months. Two patients were still alive at the end of
the study (range 23.1–133.3 months). Adjuvant treatment
after colorectal resection was performed in 50 of 73 patients
(68.3%). There was no significant improvement of overall
survival in patients with adjuvant chemotherapy versus
patients with adjuvant chemo-radiotherapy (Table 1).
Fifty-one out of 73 patients underwent adjuvant treat-
ment after metastasectomy (29 chemotherapy, two radio-
therapy, 20 chemo-radiotherapy). Adjuvant therapy after
first metastasectomy was not observed to improve long-
time survival. Additional resection for recurrent disease was
performed in two patients; both patients are alive with no
evidence of disease (Table 2).
The R0 resection group had a better outcome than the
non-resection/one-time resection group (n=56) with a
median survival of 97.8 versus 35.3 months. The difference
in survival was found to be significant (p=0.009; Fig. 2).
There were 11 men and six women, with a mean age of
58 years (range 42–72 years) at the time of primary tumour
resection. The primary site of the tumour was the colon in
nine patients and the rectum in eight patients. All patients
had initial R0 colorectal resection. In 15 patients, the
tumour was resected by laparotomy; in two patients, a
laparoscopic-assisted resection was performed (Sigma,
Coecum).
On initial presentation, three patients had UICC classi-
fication stage I disease (18%), two patients stage II (12%),
four patients stage III (23%) and eight patients stage IV
(47%). Three patients received a neoadjuvant radiochemo-
therapy before their initial colorectal resection (rectal cancer
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Fig. 1 Workflow description of
all patients with R0 resected
metastases of CRC (n = 17)
Table 1 Overall survival: adjuvant treatment after primary resection (n=73)
Number Percentage Mean survival [± (±SD) (months) Median survival (±SD) (months) Significance (log rank)
CTX 28 38.3 56.1 ± 7.4 43.2 ± 9.8 0.27
RTX 1 1.4 80.8 ± 0.0 ––
RCTX 21 28.8 41.9 ± 4.4 35.4 ± 9.0 0.9
CTX versus RCTX 0.18
No Therapy 23 31.7 46.2 ± 7.3 41.5 ± 2.8
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based chemotherapy after resection. Adjuvant chemothera-
py after colorectal resection was given in seven of our
patients (41%). All of them received additional chemother-
apy after resection of the first metastases. Two patients with
stage II rectal cancer were given neoadjuvant radiochemo-
therapy; one of them received additional chemotherapy
after resection of the primary tumour and after the resection
of the metastases as well (Table 3). The overall survival in
this patient was only 32 months. No patient had an
intraabdominal recurrence. All patients showed a normal
colonic endoscopic examination before liver or lung
surgery.
Eight patients had synchronous metastases (six liver, two
lung) and were all resected within 3 months after primary
resection; nine patients developed metachronous metastases.
Median age at the time of liver resection was 74 years
(range 46–78 years), and median time from colorectal
resection to liver metastases was 1 year (range 0–6 years).
There were 14 segmentectomies, four hepatectomies, two
liver wedge resections and three additional hyperthermic
ablations performed. The average number of liver metasta-
ses per resection was 2.5 (range 1–10).
Median time at the age of lung resection was 59 years
(range 42–74 years). Median time from colorectal resection
to lung metastases was 2.5 years (range 0–6.8 years). Two
patients underwent repeat pulmonary resections for recur-
rent disease.
Fifteen patients underwent thoracotomy for resection of
metastases; two patients were resected by thoracoscopy. One
segmentectomy, 22 wedge resections and 39 laser resections
were performed. The average number of lung metastases per
resection was 4.6 (range 1–20; Table 4). After initial
metastasectomy, the lung was the site of recurrence (n=8/
72.7%), followed by the liver (n=3/27.3%).
No postoperative mortality was observed. Follow-up was
complete in all patients and ranged from 21 to 136 months,
with a median of 54 months. Mean disease-free interval
(DFI) after resection of primary tumour was 14.1 months
(range 0–72, median 10.8 months). DFI after first meta-
stasectomy was 19.4 months (range 1.3–44.1, median
19.2 months). There was a significant impact of DFI on
OS. A disease-free interval longer than 18 months was
associated with an OS of 68.2 months (standard error 7.9,
95% confidence interval),whilst patients with a DFI <
18 months after colorectal resection had an OS of 39.3
Monaten (SD 3.6, 95% CI; p=0.001, log rank; Fig. 3). We
also analysed patient survival according to tumour stage
(UICC) as determined during surgery for CRC: Patients
with stage I disease had a median survival of 98 months,
stage II 33 months, stage III 62 months and 59 months in
stage IV. Median survival in patients with primary CRC
grades 1, 2 and 3 was 62, 47 and 98 months, respectively.
Overall, 3-, 5- and 10-year survival after primary resection
for patients with both hepatic and pulmonary metastases
(resection group) was 77%, 55% and 18%; median survival
was 98 months (Table 5 and Fig. 4). Median OS of patients
with R0 resected lung metastases of CRC was 59 months;
patients with resected hepatic lesions had a median OS of
47 months. Median survival after first metastatic resection
was 47.7 months (range 10.0–117.4 months); median
survival after second metastatic resection was 16.3 months
(range 2.0–94.5 months; Table 6).
Table 2 Overall survival: adjuvant treatment after metastasectomy (n=73)
Number Percentage Mean survival [± (±SD) (months) Median survival (±SD) (months) Significance (log rank)
CTX (curative) 33 45.2 56.3 ± 5.6 51.5 ± 5.3 0.98
CTX (palliative) 26 35.6 39.5 ± 5.5 27.7 ± 1.8 0.2
RTX 2 2.7 26.5 ± 3.6 22.9 0.01
RCTX 2 2.7 59.0 ± 16.7 35.4 0.51
Immunotherapy 2 2.7 63.4 ± 21.5 41.9 0.75
No therapy 8 11.0 58.5 ± 13.9 47.9 ± 6.4
192 168 144 120 96 72 48 24 0
Time (months)
1,0
0,8
0,6
0,4
0,2
0,0
c
u
m
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Fig. 2 Survival of patients with resected liver and lung metastases
(dotted line) versus the non-surgical group (solid line)
1132 Langenbecks Arch Surg (2010) 395:1129–1138There was no difference in OS for patients with
synchronous versus metachronous liver and lung metastases
(p=0.6).
Risk analysis was performed using univariate analysis
(chi-square). Table 7 shows survival rates as a function of
age, DFI, gender, nodal status, grading and stage of disease:
In our data, stage of disease, age and DFI were significant
prognostic factors. Multivariate analysis (Cox regression)
for >18 months DFI, stage of disease (III/UICC) and age
(<70 years) was performed: All of them were found to be
independent prognostic factors for an improved overall
survival (Table 8).
Discussion
Surgical treatment of hepatic metastases of CRC has been
reported with a 5-year survival from 30% to 39% [4, 6, 15,
Table 3 Neoadjuvant/adjuvant treatment regime in 17 patients with R0 resected colorectal liver and lung metastases
Primary resection
Year Neoadjuvant Tx Adjuvant Tx Tx after 1. Met. Tx after 2. Met.
1990 – 5-FU/Leucovorin Liver perfusion (Mitomycin C) FOLFOX
1994 – 5-FU/Leucovorin R thoracic vertebrae Tomodex
1995 –– mc Antibody Cap.
1997 – mc Antibody 5-FU mc Antibody
2000 – 5-FU (POON) (intolerance) (complication)
2001 – FOLFIRI FOLFIRI R/FOLFOX 4
2002 –– – FOLFOX 4
2002 – 5-FU (Ardalan) Cap. Cap./Oxaliplatin
2002 R/5-FU – Tx refused by patient Tx refused by patient
2003 –– FOLFIRI/Bevacizumab FUFOX/Bevacizumab
2003 R/5-FU 5-FU FOLFOX 4 FOLFOX 4
2003 – R/FOLFOX 5-FU/IT/Cetuximab Erbitux/Oxaliplatin/Cap.
2004 – FOLFOX 6 FOLFIRI FOLFIRI/Cetuximab
2004 – R/5-FU 5-FU/Oxaliplatin Bevacizumab
2006 – FOLFIRI/Bevacizumab – FOLFOX/Cetuximab
2006 – 5-FU/IT/ Bevacizumab – FOLFOX/Cetuximab
2006 R/5-FU FOLFOX Cap. FOLFIRI/Bevacizumab
Tx treatment, R radiotherapy, 5-FU 5-fluoruracil, Cap. capecitabine, IT irinotecan, FOLFOX 5-fluoruracil, oxaliplatin, leucovorin, FOLFIRI 5-
fluoruracil, leucovorin, irinotecan, mc Antibody 17-1A monoclonal antibody (Panorex®)
Mode of resection (n) Total number of resected metastases (n)
First metastasectomy
Lung Wedge resection
Liver Wedge resection 1 2
Segmentectomy 10 15
Hemihepatectomy 6 6
Thermal ablation 2 2
Radiofrequency ablation 2 2
Second metastasectomy
Lung Wedge resection 10 28
Laser resection 2 21
Segmentectomy 3 11
Lobectomy 1 5
Liver Hemihepatectomy 1 10
Segmentectomy 2 3
Table 4 Mode of resection of
liver and lung metastases
Langenbecks Arch Surg (2010) 395:1129–1138 113316], whilst the reported 5-year survival in patients with
pulmonary metastasectomy from CRC ranges from 30% to
60% [7–9, 17–20]. In our series, the results of patients with
both resection of hepatic and pulmonary metastases were in
that range (55%). Yano et al. reported a 5-year survival of
68.6% in seven patients with both hepatic and pulmonary
resection, which underlines the necessity of an aggressive
surgical approach in these patients [21]. Other authors
reported similar results [10–12, 22–25]. Our results with a
median survival of 98 months and a 5-year survival of 55%
confirm this approach. The apparently improved survival
rates for patients with resected hepatic and pulmonary
metastases compared to either isolated hepatic or pulmo-
nary metastases are presumably caused by a strict selection
of patients and a small number of patients. Multiloculary
metastatic disease provides no benefit of survival by nature.
Many patients decline metastasectomy following the initial
cancer resection for personal reasons. Furthermore, the
metastasectomy cannot be offered to a number of patients
due to reduced general condition. In our opinion, a
lowering of selection criteria will most likely lead to an
increase of resections and an assimilation of the survival
rates for patients with isolated liver or lung metastases and
patients with both liver and lung metastases. Surgical
metastasectomy should always be performed if the primary
tumour is under control and if the patient has the prospect
of complete resection, even in case of a multilocular clinical
manifestation. The presence of a systemic spread of disease
such as peritoneal carcinosis, pleural carcinosis, hepatic or
celiac metastatic lymph nodes is still a contraindication to
surgical metastasectomy, whilst the presence of even
multiple lung or liver metastases is not a contradiction to
surgical treatment. Patients with a solitary metachronous
metastases show a benefit in survival [26]. But also
simultaneous metastases do not preclude patients from a
Fig. 3 Overall survival (Kaplan–Meier) of patients <70 years (blue
line) versus >70 years (red line)
Table 5 Survival rates after primary resection
3years (%) 5years (%) 10years (%) Overall survival median (months)
Colorectal cancer 1,252 85 77 77 155
Pulmonary metastases 68 78 50 26 59
Hepatic metastases 177 63 40 17 47
Total 1,497
Both liver and lung 73
Surgical treatment (R0) 17 77 55 18 98
Non-surgical/partly surgical treatment 56 48 19 2 35
192 168 144 120 96 72 48 24 0
Time (months)
1,0
0,8
0,6
0,4
0,2
0,0
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Fig. 4 Overall survival calculated by Kaplan–Meier method for all
patients with staged hepatic and pulmonary metastasectomy in
colorectal cancer. Thick line, colorectal cancer group; thin line,
resected liver metastases; dashed line, resected lung metastases; dotted
line, R0 resected both liver and lung metastases
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Primary tumour resection First metastasectomy Second metastasectomy Status
1 34 16 13 DOD
26 0 4 9 3 0 A W D
3
a 98 98 54 DOD
4 22 10 2 DOD
5 98 26 16 DOD
6
b 59 59 28 AWD
7
b 54 54 50 AWD
8 32 15 6 DOD
9 136 117 95 AWD
10
b 48 48 15 DOD
11
b 41 41 5 NED
12 45 21 9 NED
13 29 18 8 NED
14 21 13 10 NED
15 21 17 10 NED
16 62 17 7 AWD
17 28 20 19 DOD
Table 6 Survival of patients
undergoing hepatic and pulmo-
nary resection for colorectal
metastases
DOD dead of disease, AWD
alive with disease, NED no
evidence of disease
aSimultaneous resection of pri-
mary tumour and pulmonary
metastases
bSimultaneous resection of pri-
mary tumour and hepatic
metastases
Table 7 Risk factors for overall survival in patients with colorectal liver and lung metastases (n=73)
Predictors for overall survival with reference to primary resection (univariate analysis)
Number Mean interval ± SD Median interval (months) ± SD p value
Age <65 years 46 58.7 ± 6.1 51.5 ± 5.1
>65 years 27 37.1 ± 3.4 33.1 ± 3.1 0.06
<70 years 55 56.7 ± 5.5 47.7 ± 6.6
>70 years 18 34.3 ± 3.6 30.1 ± 6.7 0.02
<75 years 66 52.8 ± 4.7 43.3 ± 6.5
>75 years 7 33.1 ± 5.1 33.1 ± 8.7 0.032
Gender Male 53.7 ± 5.5 43.2 ± 7.2
Female 44.9 ± 5.6 41.5 ± 5.4 0.29
DFI <18 months 48 39.5 ± 3.5 33.9 ± 2.4
>18 months 25 68.2 ± 7.9 62.1 ± 11.1 0.001
<24 months 60 44.2 ± 4.2 35.3 ± 4.7
>24 months 13 76.1 ± 10.5 67.5 ± 8.4 0.01
Nodal status Positive 48 48.6 ± 4.7 54.5 ± 8.6
Negative 25 43.3 ± 8.5 41.5 ± 2.8 0.618
Grading G2 49.7 ± 5.2 41.5 ± 7.1 0.8
G3 53.3 ± 7.3 43.3 ± 11.1 0.7
Dukes A 6 67.3 ± 19.4 38.3 ± 7.8 0.252
B 17 44.4 ± 4.5 41.5 ± 6.0 0.638
C 34 46.8 ± 5.7 35.4 ± 6.7 0.362
D 16 54.7 ± 8.9 51.5 ± 13.8 0.525
T-stage 1 2 22.4 ± 6.4 16.0 0.006
2 10 62.9 ± 18.1 72.8 ± 15.4 0.063
3 53 49.4 ± 4.7 41.9 ± 6.6 0.603
4 8 39.5 ± 8.1 31.9 ± 2.4 0.274
Langenbecks Arch Surg (2010) 395:1129–1138 1135possible curative resection, and the survival rates in patients
with simultaneous metastases are reported with an equal
morbidity and outcome as in patients with metachronous
metastases [27, 28]. Bilateral or multiple pulmonary
metastases or bilateral hepatic lesions are generally accept-
ed for surgical resection when curative resection is possible.
Kobayashi et al. reported a significant difference in the
cumulative survival for patients with a solitary pulmonary
metastasis versus multiple metastases, whereas the number
or resected hepatic lesions did not seem to influence
outcome [29].
In the current study, patients with a DFI of more than
18 months had a significant impact on OS versus patients
with a DFI < 18 months. Sato and colleagues reported
similar results in patients with isolated liver metastases of
CRC. A prolonged DFI was one of the most important
factors for OS [30, 31]. Other prognostic variables such as
CEA level or number of lesions are also known to affect
survival, but none of them is generally accepted to be an
absolute contraindication for surgical resection. Headrick et
al. [32] reported the presence of lymph node metastases
within the chest as one possible contraindication. They
identified four patients in their series with positive thoracic
lymph nodes who demonstrated a short DFI and a limited
survival. These results were trend-setting but not statisti-
cally significant.
The surgical approach was also discussed with regards to
affecting survival. For primary tumour resection, we
performed a standard laparotomy in 15 patients; in two
patients, we performed a laparoscopic-assisted colectomy.
The method of resection of hepatic and pulmonary
metastases in our patients did not influence the outcome.
We used an anterolateral thoracotomy as the standard
approach in most of our patients. In those patients with a
single pulmonary lesion, we used video-assisted thoraco-
scopic surgery. One patient with multiple lesions (n=20)
was treated with laser ablation at the time of thoracotomy.
The standard approach for hepatic metastases was a median
laparotomy in all patients. The surgical approach did not
appear to influence patient outcome. Other authors have
reported similar results [33, 34].
For patients with stage III colon cancer, adjuvant
chemotherapy is widely accepted, whereas in stage II
disease, no significant benefit is reported [35, 36]. Adjuvant
chemo-radiotherapy for rectal cancer is indicated in stage II
or stage III and in patients where radical (R0) resection
could not have been reached [37]. Whilst the value of
adjuvant therapy of CRC after initial resection is clear, the
value of adjuvant therapy after metastasectomy of CRC is
not clarified at all. In four international studies, recruiting
more than 3,300 patients with resected hepatic metastases
of CRC, no significant benefit of an adjuvant therapy after
metastasectomy could be detected. The 5-year survival rate
after resection of hepatic metastases of CRC was 28–39%
irrespective of any adjuvant therapy [38, 39]. In the world
literature, there is no evidence of a prolonged survival for
adjuvant chemotherapy following pulmonary metastasec-
tomy of CRC [40]. Adjuvant chemotherapy after lung
resection is therefore not recommended as a standardised
therapy should only take place within controlled studies.
Patients treated with adjuvant chemotherapy both after
primary resection and metastasectomy had a mean survival
of 76.6 months, whilst patients without adjuvant therapy
achieved a mean survival of 58.7 months. In our series, the
OS for patients with adjuvant chemotherapy after meta-
stasectomy was not significantly improved. Besides, a
substantial comparison of the (neo)-adjuvant therapy is
neither possible nor meaningful due to the long investiga-
tion period (18 years). New chemotherapeutic substances,
changing application doses, modified therapy patterns or
combination therapies do not permit a comparative conclu-
sion. Repeated metastasectomy for recurrent hepatic or
pulmonary metastases has been carried out with no increase
in either morbidity or mortality. Repeat metastasectomy by
laparotomy or thoracotomy will be offered to any selected
patient who can tolerate further resection.
Due to its nature, this retrospective study cannot provide
evidence for an advantage of surgical treatment over non-
surgical treatment in multiloculary metastatic colorectal
cancer. Furthermore, the patient population is limited by
high selection. However, the excellent survival rates for
selected patients achieved by aggressive surgical therapy
Predictors for overall survival with reference to primary resection (multivariate analysis)
95% CI Mean interval (months) ± SD p value
DFI >18 months 02.1–0.69 39.3 ± 3.5 0.001
T-stage T2 0.02–0.38 72.8 ± 15.4 0.05
Age <70 years 1.5–5.5 56.7 ± 5.5 0.001
Stage III (Dukes C) 0.2–0.68 46.8 ± 5.7 0.001
Age <75 years 1.62–7.85 52.8 ± 4.7 0.062
Table 8 Risk factors for overall
survival in patients with colo-
rectal liver and lung metastases
(n=73)
DFI disease-free interval, T2
stage III: TNM classification of
malignant tumours [13]
1136 Langenbecks Arch Surg (2010) 395:1129–1138adduce empirical evidence bearing comparison with non-
surgical treatment. But a prospective study comparing
surgical treatment of metastatic CRC versus non-surgical
treatment is ethically not feasible since—according to
oncological guidelines—all patients with resectable liver
or lung metastases of CRC (as the first metastases)
should be resected. Lung or liver resection is still the
only curative treatment for selected patients with meta-
static CRC. The long-term survival in our selected group
of patients with both resected liver and lung metastases
from CRC is comparable to solitary liver or lung
metastases. From a surgical point of view, every attempt
must be made to increase the availability of any liver or lung
resection [41].
Today, the treatment of metastatic colorectal cancer
should be performed in a multidisciplinary way, including
surgeons, medical oncologists and radiotherapists.
Surgical treatment of even multiple hepatic and pulmo-
nary metastases of colorectal cancer results in significantly
increased survival time compared with patients without a
surgical approach. In association with new effective
chemotherapies, including immunoglobulin monoclonal
antibodies, even long-term survival can be achieved.
Conclusion
Patients with synchronous or metachronous hepatic and
pulmonary metastases of colorectal carcinoma should always
be considered for a possible surgical resection as it offers a
valid therapeutic opportunity with excellent survival rates.
An aggressive surgical approach in a specialised centre is
safe with low morbidity and low mortality and offers an
excellent chance for long-term survival. Overall survival for
surgically treated selected patients with both hepatic and
pulmonary metastases from CRC is comparable to hepatic or
pulmonary metastasectomy.
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